Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation and Depletion: 2014-2024

Historic Depreciation and Depletion for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $1.2 million.

  • Cartesian Therapeutics' Depreciation and Depletion rose 100.00% to $600,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 155.56%. This contributed to the annual value of $1.2 million for FY2024, which is 71.43% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Depreciation and Depletion is $1.2 million, which was up 71.43% from $700,000 recorded in FY2023.
  • Cartesian Therapeutics' Depreciation and Depletion's 5-year high stood at $1.2 million during FY2024, with a 5-year trough of $600,000 in FY2020.
  • Over the past 3 years, Cartesian Therapeutics' median Depreciation and Depletion value was $700,000 (recorded in 2023), while the average stood at $866,667.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first fell by 14.29% in 2020, then spiked by 71.43% in 2024.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Depreciation and Depletion stood at $600,000 in 2020, then remained steady at $600,000 in 2021, then rose by 16.67% to $700,000 in 2022, then remained steady at $700,000 in 2023, then surged by 71.43% to $1.2 million in 2024.